DR-269 Investigating the Role of EMT-mediated Immunotherapy Resistance
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-269 Investigating the Role of EMT-mediated Immunotherapy Resistance
The cellular process of epithelial-to-mesenchymal transition (EMT) facilitates the spread of tumors (metastasis) and is involved in therapy resistance, however …
DR-284 Somatic mutations in non-coding RNA genes associated with cancer pathways
We wish to study the non-coding RNA genes and their somatic mutations in cancer. We have analysed the somatic mutations …
DR-196 Clinical and Genomic landscape of Carcinoma of Unknown Primary in the Netherlands, compared to metastasised known primary tumours
Patients with carcinoma of unknown primary (CUP) are patients with proven metastases but no primary tumour found. These patients have …
DR-271 Population genomics study to uncover the role of rare variants in heritable risk of sarcoma
Sarcoma is a rare and complex cancer with poor prognosis and survival. While existing genetic studies in cancer have focused on …
DR-197 In-depth molecular characterization of liver metastases from BC patients
One out of 8 women will develop breast cancer (BC) in her lifetime and BC remains the main cause of …
DR-261 Chromosomal instability as key regulator of the immune microenvironment of cancers
Immune cells in the microenvironment of cancers impact disease progression and response to both conventional therapies and immune checkpoint blockers. …
DR-288 The Molecular Profile of Lynch Syndrome-Associated Carcinomas
Patients with Lynch Syndrome (LS) carry a mutation in MLH1, MSH2 (EPCAM), MSH6 or PMS2 and as a result have a genetic predisposition to …
DR-214 Genomic landscape of tumor sensitivity and resistance to anti-cancer drugs in colorectal cancer patients
Colorectal cancer (CRC) ranks as the second most lethal cancer and the third most prevalent malignant tumor worldwide. Despite of …
DR-259 Role of DNA Damage Tolerance Pathways in Genome Maintenance: Linking Mutations to the Lack of DDT
DNA damage response (DDR) network is critical in maintaining genome integrity. The contribution of the DNA damage tolerance (DDT) system …
DR-217 Metastatic breast cancer: can liquid biopsies reliably replace solid biopsies?
There is no cure for metastatic breast cancer, but there are still many treatment options that may prolong life with …
Dr-304 Characterization of genomic alterations in metastatic cutaneous squamous cell carcinoma and basal cell carcinoma
Every year >14,000 patients are diagnosed with cutaneous squamous cell carcinoma (cSCC) and > 35,000 new patients with basal cell …
DR-244 Discovery of mutational signatures associated with chemotherapeutic treatment of cancer
1. Mutational signatures are patterns of mutations that inform us of the mutational process underlying tumorigenesis. We will investigate the mutational …
Er komen steeds meer oncologische geneesmiddelen beschikbaar die maar voor een klein deel van de patiënten geschikt zijn. Op dit moment vinden we die patiënten niet. Bij élke patiënt met uitgezaaide kanker zou uitgebreide genetische screening moeten plaatsvinden.